QSAM Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Going Concern (Details Narrative)

Basis of Presentation and Going Concern (Details Narrative) - USD ($)					1 Months Ended		3 Months Ended				6 Months Ended
	Apr. 20, 2020	Jan. 18, 2019	Nov. 09, 2018	Jun. 30, 2017	May 31, 2019	Jun. 30, 2018	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net cash used in operating activities											$ (346,492)	$ (196,094)
Net loss							$ (872,645)	$ (437,402)	$ (812,697)	$ (505,274)	(1,310,046)	(1,317,971)
Accumulated deficit							(12,359,257)				(12,359,257)		$ (11,049,210)
Debentures							165,000				$ 165,000		165,000
Debentures and redeemable convertible preferred stock, maturity date											Jul. 01, 2019
Convertible bridge notes							2,771,908				$ 2,771,908
Convertible bridge notes and accrued interest maturity description											Convertible bridge notes plus accrued and capitalized interest of $1,323,636, began to mature through October 2020, with an additional $35,251 in principal and accrued interest maturing in 2021.
Capitalized interest							1,322,262				$ 1,322,262
Working capital deficit							5,029,367				5,029,367
Face amount of debt							2,801,908				2,801,908
Accrued interest											1,329,000
Payment for consulting							79,459		$ 80,611		154,682	$ 222,597
Employee Owned Nursery Enterprises Ltd [Member]
Annual management fee		$ 500,000
Class B Units [Member] \| Employee Owned Nursery Enterprises Ltd [Member]
Number of shares acquired in acquisition		53,970
Number of shares acquired in acquisition, value		$ 21,588
Follow-On Investments [Member]
Face amount of debt															$ 600,000
Follow-On Bridge Offering [Member]
Debt converted amount						$ 50,000
Follow-On Bridge Offering [Member] \| Three Accredited Investors and One Institutional Investor [Member]
Face amount of debt													$ 30,000	$ 980,000
Tranche One [Member]
Debt converted amount				$ 1,050,000
Mature Through October 2020 [Member]
Convertible bridge notes							$ 35,251				35,251
Eight-Year Management Agreement [Member]
Annual management fee			$ 200,000
Eight-Year Management Agreement [Member] \| George B. Wittmer Associates Inc. [Member]
Annual management fee			300,000
Eight-Year Management Agreement [Member] \| Subsequently Increased by Amendment [Member]
Annual management fee			$ 700,000
EPH's Limited Liability Company Agreement [Member] \| Class B Units [Member]
Number of shares acquired in acquisition			124,999
Voting interests, acquired			19.90%
Number of shares acquired in acquisition, value			$ 50,000
Transfer Agreement [Member] \| One Institutional Investor [Member] \| Class A Units [Member]
Issuance of private placement offering amount			$ 4,400,000
Number shares issued during period			500,000
Transfer Agreement [Member] \| One Institutional Investor [Member] \| Class A Units [Member] \| Earth Property Holdings LLC [Member]
Equity method investment ownership percentage			80.10%
Service Agreement [Member] \| CECO Power, LLC [Member]
Royalty fee											7,500
Accrued royalty fee											$ 30,000
Service Agreement [Member] \| CECO Power, LLC [Member] \| Two Waste-To-Power Facilities [Member]
Service fees					$ 250,000
License Agreement [Member]
Equity method investment ownership percentage	5.00%
Payments for milestone	$ 60,000
Other expense reimbursements	150,000
Payments for commercialization	$ 1,500,000
Royalty percentage	4.50%
Agreement description	The License Agreement is for 20 years or until the expiration of the multiple patents covered under the license, and requires multiple milestone based payments including: $60,000 and other expense reimbursements within 60 days of signing, up to $150,000 as the Technology advances through multiple stages of clinical trials, and $1.5 million upon commercialization. IGL will also receive equity in QSAM equal to 5% of the company to be issued within 60 days of signing. Upon commercialization, IGL will receive an on-going royalty equal to 4.5% of Net Sales, as defined in the License Agreement, and up to 50% of any Sublicense Consideration received by QSAM, as defined in the License Agreement.
Repayment direct clinical costs percentage	25.00%
License Agreement [Member] \| Maximum [Member]
Royalty percentage	50.00%
Consulting Agreement [Member]
Agreement description	The License Agreement, QSAM signed a two-year Consulting and Confidentiality Agreement (the “Consulting Agreement”) with IGL, which provides IGL with payments of $8,500 per month starting 60 days after signing.
Payment for consulting	$ 8,500